Low-Dose darbepoetin α attenuates progression of a mouse model of aristolochic acid nephropathy through early tubular protection

Nephron - Experimental Nephrology

Volumn 114, Issue 2, 2010, Pages

  Hamano, Yuki ^a   Aoki, Takahiro ^b   Shirai, Ryota ^b   Hatano, Megumi ^b   Kimura, Ryota ^b   Ogawa, Makoto ^a,c   Yokosuka, Osamu ^c   Ueda, Shiro ^b  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b Sch Pharmaceutical Sci Toho U   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Acute tubular necrosis; Aristolochic acid nephropathy; Darbepoetin ; Interstitial fibrosis

Indexed keywords

ARISTOLOCHIC ACID; CREATININE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ACUTE KIDNEY TUBULE NECROSIS; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARISTOLOCHIC ACID NEPHROTPATHY; ARTICLE; CAPILLARY; CELL SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; HEMATOCRIT; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; KIDNEY TUBULE DAMAGE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION;

ANIMALS; APOPTOSIS; ARISTOLOCHIC ACIDS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; FIBROSIS; KIDNEY TUBULAR NECROSIS, ACUTE; KIDNEY TUBULES; MALE; MICE; MICE, INBRED C3H;

EID: 70449512992     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000256569     Document Type: Article

References (44)

1. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994; 91: 3974-3978.
2. Chong ZZ, Kang JQ, Maiese K: Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 2973-2979.
3. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007.
4. Sharples EJ, Thiemermann C, Yaqoob MM: Mechanisms of disease: cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephrol 2005; 1: 87-97.
5. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, Kirsch T, de Groot K, Laudeley R, Niemczyk E, Guler F, Menne J, Haller H, Fliser D: Lowdose therapy with the long-acting erythropoietin analogue darbepoetin α persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012.
6. Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, Kurihara H, Kawachi H, Shankland SJ, Fujita T, Nangaku M: Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007; 72: 455-463.
7. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC: Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806-1813.
8. Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ: Darbepoetin α protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007; 72: 489-498.
9. Cases A: Darbepoetin α a novel erythropoiesis-stimulating protein. Drugs Today (Barc) 2003; 39: 477-495.
10. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, et al: Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387-391.
11. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL: Urothelial carcinoma associated with the use of a Chinese herb (aristolochia fangchi). N Engl J Med 2000; 342: 1686-1692.
12. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP: Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996; 56: 2025-2028.
13. Cosyns JP: Aristolochic acid and "Chinese herbs nephropathy": a review of the evidence to date. Drug Saf 2003; 26: 33-48.
14. Liu MC, Maruyama S, Mizuno M, Morita Y, Hanaki S, Yuzawa Y, Matsuo S: The nephrotoxicity of Aristolochia manshuriensis in rats is attributable to its aristolochic acids. Clin Exp Nephrol 2003; 7: 186-194.
15. Mengs U: Acute toxicity of aristolochic acid in rodents. Arch Toxicol 1987; 59: 328-331.
16. Mengs U, Stotzem CD: Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch Toxicol 1993; 67: 307-311.
17. Depierreux M, Van Damme B, Vanden Houte K, Vanherweghem JL: Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 1994; 24: 172-180.
18. Reginster F, Jadoul M, van Ypersele de Strihou C: Chinese herbs nephropathy presentation, natural history and fate after transplantation. Nephrol Dial Transplant 1997; 12: 81-86.
19. Yang L, Li X, Wang H: Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. Nephrol Dial Transplant 2007; 22: 445-456.
20. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelic M, Jelakovic B: Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 2007; 104: 12129-12134.
21. Melnikov VY, Faubel S, Siegmund B, Lucia MS, Ljubanovic D, Edelstein CL: Neutro-phil-independent mechanisms of caspase-1-and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 2002; 110: 1083-1091.
22. Hamano Y, Grunkemeyer JA, Sudhakar A, Zeisberg M, Cosgrove D, Morello R, Lee B, Sugimoto H, Kalluri R: Determinants of vascular permeability in the kidney glomerulus. J Biol Chem 2002; 277: 31154-31162.
23. Fujii T, Hamano Y, Ueda S, Akikusa B, Yamasaki S, Ogawa M, Saisho H, Verbeek JS, Taki S, Saito T: Predominant role of Fc γ RIII in the induction of accelerated nephrotoxic glomerulonephritis. Kidney Int 2003; 64: 1406-1416.
24. Pozdzik AA, Salmon IJ, Debelle FD, Decaestecker C, Van den Branden C, Verbeelen D, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL: Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 2008; 73: 595-607.
25. Sun D, Feng J, Dai C, Sun L, Jin T, Ma J, Wang L: Role of peritubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy. Am J Nephrol 2006; 26: 363-371.
26. Kazama I, Matsubara M, Michimata M, Suzuki M, Hatano R, Sato H, Ito S: Adult onset Fanconi syndrome: extensive tubulo-inter-stitial lesions and glomerulopathy in the early stage of Chinese herbs nephropathy. Clin Exp Nephrol 2004; 8: 283-287.
27. Brines M, Cerami A: Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484-494.
28. Fliser D, Bahlmann FH, deGroot K, Haller H: Mechanisms of disease: erythropoietin an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006; 3: 563-572.
29. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, Thiemermann C: Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004; 66: 983-989.
30. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 2115-2124.
31. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, Sun BK, Kim YS, Kim J, Chang YS, Bang BK: Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17: 1754-1755.
32. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D: The continuous erythro-poietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007; 18: 2046-2053.
33. Fliser D, Bahlmann FH, Haller H: EPO: Renoprotection beyond anemia correction. Pediatr Nephrol 2006; 21: 1785-1789.
34. Fuste B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, Ordinas A, Diaz-Ricart M: Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 678-685.
35. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B: Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-2989.
36. Wang W, Zhang J: Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol 2008; 588: 135-140.
37. Westenfelder C, Biddle DL, Baranowski RL: Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808-820.
38. Pozdzik AA, Salmon IJ, Husson CP, Decaestecker C, Rogier E, Bourgeade MF, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL: Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy. Nephrol Dial Transplant 2008; 23: 2480-2491.
39. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198: 971-975.
40. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
41. Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
42. Zeisberg M, Kalluri R: The role of epithelialto-mesenchymal transition in renal fibrosis. J Mol Med 2004; 82: 175-181.
43. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007; 117: 3810-3820.
44. 1/Smad7 signaling stimulates renal tubulointerstitial fibrosis induced by AAI. J Recept Signal Transduct Res 2008; 28: 413-428.